Oksana Shlobin
Overview
Explore the profile of Oksana Shlobin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
87
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Price L, Kouranos V, Baughman R, Bloom C, Stewart I, Shlobin O, et al.
Sarcoidosis Vasc Diffuse Lung Dis
. 2024 Apr;
41(1):e2024024.
PMID: 38567554
No abstract available.
2.
Thomas C, Chandel A, King C, Aryal S, Brown A, Khangoora V, et al.
Pulm Circ
. 2023 Apr;
13(2):e12228.
PMID: 37091120
COVID-19 related lung disease (CRLD) has emerged as an indication for lung transplantation (LT) in highly select patients. The prevalence and prognostic implication of coexisting pulmonary hypertension (PH) in patients...
3.
Wigerblad G, Warner S, Ramos-Benitez M, Kardava L, Tian X, Miao R, et al.
Sci Adv
. 2023 Jan;
9(1):eade8272.
PMID: 36598976
Spleen tyrosine kinase (SYK) is a previously unidentified therapeutic target that inhibits neutrophil and macrophage activation in coronavirus disease 2019 (COVID-19). Fostamatinib, a SYK inhibitor, was studied in a phase...
4.
Zhou C, Sahay S, Shlobin O, Soto F, Mathai S, Melendres-Groves L, et al.
Respir Med
. 2022 Dec;
206:107061.
PMID: 36493604
The coronavirus of 2019 (COVID-19) disrupted delivery of healthcare. Patients with pulmonary hypertension (PH), especially pulmonary arterial hypertension (PAH), require significant resources for both diagnosis and management and are at...
5.
Grinnan D, Kang L, DeWilde C, Badesch D, Benza R, Bull T, et al.
Pulm Circ
. 2022 Aug;
12(3):e12120.
PMID: 35911181
Outcomes of patients with pulmonary arterial hypertension (PAH) may be associated with social determinants of health (SDOH) and other baseline patient characteristics. At present, there is no prognostic model to...
6.
Sahay S, Balasubramanian V, Memon H, Poms A, Bossone E, Highland K, et al.
Pulm Circ
. 2022 May;
12(2):e12057.
PMID: 35514787
Pulmonary arterial hypertension (PAH) is a chronically progressive fatal disease. A goal-oriented approach to achieve low risk status has been associated with improved survival. A variety of risk stratification tools...
7.
Savale L, Huitema M, Shlobin O, Kouranos V, Nathan S, Nunes H, et al.
Eur Respir Rev
. 2022 Feb;
31(163).
PMID: 35140103
Sarcoidosis-associated pulmonary hypertension (SAPH) is an important complication of advanced sarcoidosis. Over the past few years, there have been several studies dealing with screening, diagnosis and treatment of SAPH. This...
8.
Strich J, Tian X, Samour M, King C, Shlobin O, Reger R, et al.
Clin Infect Dis
. 2021 Sep;
75(1):e491-e498.
PMID: 34467402
Background: Coronavirus disease 2019 (COVID-19) requiring hospitalization is characterized by robust antibody production, dysregulated immune response, and immunothrombosis. Fostamatinib is a novel spleen tyrosine kinase inhibitor that we hypothesize will...
9.
Fakhri S, Hannon K, Moulden K, Peterson R, Hountras P, Bull T, et al.
Pulm Circ
. 2020 Nov;
10(4):2045894020964342.
PMID: 33240488
Background: WHO Group 1 pulmonary arterial hypertension is a progressive and potentially fatal disease. Individuals living at higher altitude are exposed to lower barometric pressure and hypobaric hypoxemia. This may...
10.
Min J, Badesch D, Chakinala M, Elwing J, Frantz R, Horn E, et al.
Am J Respir Crit Care Med
. 2020 Nov;
203(6):761-764.
PMID: 33211974
No abstract available.